Alector vs LENZ Therapeutics
Alector reported revenue of $21 million in fiscal 2025, about the same as LENZ Therapeutics' $19 million in fiscal 2025. Alector had an operating margin of -741.3%, against -477.5% at LENZ Therapeutics. Free cash flow was −$184 million at Alector and −$70 million at LENZ Therapeutics.
Side by side
| Alector | LENZ Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $21M | $19M |
| Revenue growth | −79.1% | — |
| Revenue growth a year, last 5 years | −0.1% | — |
| Gross margin | — | 97.8% |
| Operating margin | −741.3% | −477.5% |
| Net margin | −679.2% | −430.2% |
| Free cash flow | −$184M | −$70M |
| Free cash flow margin | −874.7% | −366.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.6% | 35.4% |
| Last close | $2.30 | $3.34 |
| P/E at the last close | 6.6× | — |
| Insider trades, last 12 months | sold $1.0 million | bought $365,553, sold $0 |
| Piotroski F-score | 1 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlectorLENZ Therapeutics
Operating margin
Percent of revenue
AlectorLENZ Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlectorLENZ Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alector and LENZ Therapeutics pages.